Key points are not available for this paper at this time.
Novo Nordisk is using some of the profit from its weight-loss drugs to form a partnership with Neomorph, a start-up backed by Deerfield Management. The Danish firm will pay Neomorph an unspecified amount up front and up to 1. 46 billion in milestone payments across multiple targets. The drugs in the collaboration are molecular glues—small molecules that degrade harmful proteins. Neomorph launched in late 2020 with 109 million to develop such treatments.
Rowan Walrath (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: